Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Shanghai Pharmaceuticals Commits $42M to SIIC Bio-Med Fund Targeting FIC/BIC Assets from IND to Phase II

Fineline Cube Jul 22, 2026
Company Deals

TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal

Fineline Cube Jul 22, 2026
Company Deals

Trinomab Biotechnology Debuts on Shanghai STAR Market with First-in-Class Anti-Tetanus Monoclonal Antibody

Fineline Cube Jul 22, 2026
Company Deals

Grand Pharma Partners with Siemens Healthineers to Commercialize AcuNav Lumos 4D ICE Catheter in China’s Structural Heart Market

Fineline Cube Jul 21, 2026
Company Deals Digital

Insilico Medicine Forms Quantum-AI Alliance with Byterna and DuneQ to Accelerate Next-Generation RNA and Peptide Therapeutics

Fineline Cube Jul 21, 2026
Policy / Regulatory

Trump Announces Phased Tariff Policy on Generic Drug Imports to Incentivize U.S. Manufacturing Reshoring

Fineline Cube Jul 23, 2026
Company Drug

GSK Secures Early FDA Approval for Jideytro – ROS1 Inhibitor for Resistant Non-Small Cell Lung Cancer

Fineline Cube Jul 23, 2026
Company Drug

Pfizer Secures FDA Priority Review for TALZENNA-XTANDI Combination in Earlier-Stage Prostate Cancer

Fineline Cube Jul 23, 2026
Company Drug

Hengrui Pharmaceuticals Gains NMPA Approval for Phase Ib/II Study of SHR-A1811, Adebrelimab and Famitinib in Solid Tumors

Fineline Cube Jun 6, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received approval from...

Company Deals

Qure Biotechnology Secures RMB 100 Million Series C1 Financing

Fineline Cube Jun 6, 2025

China-based Qure Biotechnology (Shanghai) Co., Ltd. announced the completion of a Series C1 financing round...

Company Drug

Lianhuan Pharma Gains NMPA Approval for No-Spa Generic

Fineline Cube Jun 6, 2025

China-based Jiangsu Lianhuan Pharmaceutical Co., Ltd (SHA: 600513) announced that it has received market clearance...

Company Drug

Roche’s Evrysdi 5mg Tablet Gains EU Commission Approval for Spinal Muscular Atrophy

Fineline Cube Jun 6, 2025

Swiss giant Roche AG (SWX: ROG, OTCMKTS: RHHBY) announced that the European Commission (EC) has...

Company Deals

Shanghai OPM Biosciences Plans Acqusition of PharmaLegacy Labs for RMB 1.45 Billion

Fineline Cube Jun 6, 2025

Shanghai OPM Biosciences Co., Ltd (SHA: 688293), a China-based cell culture-focused Contract Development and Manufacturing...

Company Drug

Sunshine Guojian’s SSGJ-613 Meets Phase III Endpoints in Acute Gouty Arthritis

Fineline Cube Jun 6, 2025

China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), announced...

Policy / Regulatory

NHSA Strengthens Pharmaceutical Pricing and Procurement Credit Evaluation Mechanism

Fineline Cube Jun 6, 2025

The National Healthcare Security Administration (NHSA) issued a notification this week to refine its credit...

Policy / Regulatory

China Issues Whistleblower Incentives for Drug and Medical Device Safety Violations

Fineline Cube Jun 6, 2025

China’s National Medical Products Administration (NMPA), Ministry of Finance (MoF), and State Administration for Market...

Policy / Regulatory

China’s National Health Commission Mandates Labor Pain Management Services Expansion

Fineline Cube Jun 6, 2025

China’s National Health Commission (NHC) issued a notification mandating the comprehensive promotion of labor pain...

Company Deals

Intragrand Pharma Licenses Lenamilast to Transpire Bio for Global Development

Fineline Cube Jun 6, 2025

China-based Suzhou Intragrand Pharma has entered into a licensing agreement with U.S.-headquartered Transpire Bio Inc....

Company Deals

Consun Pharma Partners with DP Technology to Accelerate AI-Driven Kidney Disease Drug R&D

Fineline Cube Jun 6, 2025

China-based Consun Pharmaceutical Group Ltd (HKG: 1681) announced a strategic partnership with compatriot firm DP...

Company Drug

Innovent Biologics’ IBI363 Receives Breakthrough Therapy Designation from CDE

Fineline Cube Jun 5, 2025

China-based Innovent Biologics, Inc. (HKG: 1801) announced that its first-in-class PD-1/IL-2α-bias bispecific antibody (BsAb) fusion...

Company Drug

BMS Secures NMPA Approval for Reblozyl in Myelodysplastic Syndromes

Fineline Cube Jun 5, 2025

US-based multinational Bristol-Myers Squibb (BMS, NYSE: BMY) announced that it has received an indication extension...

Company Deals

Shanghai Pharma Partners with Chugai Pharma China to Enhance Bone Health Products

Fineline Cube Jun 5, 2025

China’s Shanghai Pharmaceuticals Holding Co., Ltd. (HKG: 2607, SHA: 601607; SPH) has established a partnership...

Company Deals

Genrix Bio Partners with Cullinan Therapeutics for GR1803 License

Fineline Cube Jun 5, 2025

China-based Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) announced a licensing agreement with Cullinan Therapeutics,...

Company Drug

AstraZeneca’s Imfinzi Approved for Limited Stage Small Cell Lung Cancer in China

Fineline Cube Jun 5, 2025

UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) received approval from China’s National Medical Products Administration...

Company Drug

Akeso Biopharma Wins NMPA Approval for New Cadonilimab Indication

Fineline Cube Jun 5, 2025

China-based Akeso Biopharma (HKG: 9926) announced that it has received another indication approval from the...

Company Drug

Salubris Pharmaceuticals’ Allisartan-Indapamide Hybrid Wins NMPA Approval

Fineline Cube Jun 5, 2025

Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294), a Chinese pharmaceutical company, announced that it has...

Company Drug

Wantai Biopharm’s Cecolin 9 HPV Vaccine Approved by China’s NMPA

Fineline Cube Jun 5, 2025

China-based Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHA: 603392) announced that its 9-valent human...

Company Drug

Biocytogen and Chia Tai Tianqing Win NMPA Approval for NTB003 Clinical Trials

Fineline Cube Jun 5, 2025

Chinese partners Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) and Chia Tai Tianqing announced that...

Posts pagination

1 … 181 182 183 … 698

Recent updates

  • Trump Announces Phased Tariff Policy on Generic Drug Imports to Incentivize U.S. Manufacturing Reshoring
  • GSK Secures Early FDA Approval for Jideytro – ROS1 Inhibitor for Resistant Non-Small Cell Lung Cancer
  • Pfizer Secures FDA Priority Review for TALZENNA-XTANDI Combination in Earlier-Stage Prostate Cancer
  • Ribo Life Science Reports Positive Phase 2a Results for Vortosiran in Chronic Coronary Artery Disease
  • Johnson & Johnson Secures FDA De Novo Authorization for OTTAVA™ – World’s First Table-Integrated Robotic Surgical System
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

Trump Announces Phased Tariff Policy on Generic Drug Imports to Incentivize U.S. Manufacturing Reshoring

Company Drug

GSK Secures Early FDA Approval for Jideytro – ROS1 Inhibitor for Resistant Non-Small Cell Lung Cancer

Company Drug

Pfizer Secures FDA Priority Review for TALZENNA-XTANDI Combination in Earlier-Stage Prostate Cancer

Company Drug

Ribo Life Science Reports Positive Phase 2a Results for Vortosiran in Chronic Coronary Artery Disease

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.